Management and treatment of severe immune-related hepatotoxicity based on clinical and pathological characteristics.

ABSTRACT:

Background

The management of severe immune-related hepatotoxicity (irH) needs to be further optimized. This study aims to analyze the clinical characteristics of severe irH; improve the therapeutic strategy, especially salvage treatment in steroid-refractory irH; and determine the safety of immune checkpoint inhibitor (ICPi)-rechallenge.

Methods

This multicenter retrospective study included patients who developed severe irH and those without irH after immunotherapy between May 2019 and June 2023. Propensity score matching was used to match these two cohorts with similar baseline characteristics.

Results

Among 5,326 patients receiving ICPis, 51 patients developed severe irH. irH occurred after a median duration of 36 days and a median of two doses after the first ICPi

SUBMITTER: Zhang N 

PROVIDER: S-EPMC11632075 | biostudies-literature | 2024 Dec

REPOSITORIES: biostudies-literature